Heteronemin combined with tetrac appeared to reduce the expression level of signal transduction pathways involved in EGFR signaling, which includes cell proliferation, angiogenesis, and epithelial–mesenchymal transition (EMT) in tumor metastasis compared to heteronemin alone. This evidence concerns the gene EGFR and neoplasm.